Impact of new technologies for cellular screening along the drug value chain.
High-information screening formats, using more physiologically relevant cellular models and readout approaches, are slowly replacing traditional, target-orientated approaches in drug discovery programs. With improved access to primary cells, as well as label-free, non-intrusive methods of compound interrogation (such as automated electrophysiology), high-thoughput screening facilities have to adapt to more complex assay scenarios. The implementation of novel cellular systems, readout technologies and data management in a drug discovery company are essential to improve the current falling productivity evident in recent years throughout the pharmaceutical industry.
Möller
Clemens
C
Evotec AG, Schnackenburgallee 114, 22525 Hamburg, Germany. clemens.moeller@evotec.com
Slack
Mark
M
D000818:Animals; D001681:Biological Assay / Q000295:instrumentation* / Q000379:methods*; D055808:Drug Discovery / Q000379:methods*; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D057166:High-Throughput Screening Assays / Q000379:methods*; D006801:Humans; D007473:Ion Channels / Q000187:drug effects; D018625:Microscopy, Atomic Force / Q000379:methods; D018408:Patch-Clamp Techniques / Q000295:instrumentation / Q000379:methods; D011956:Receptors, Cell Surface / Q000187:drug effects; D013234:Stem Cells / Q000187:drug effects*
D007473:Ion Channels; D011956:Receptors, Cell Surface